SCHEMBL6584876

SCHEMBL6584876

C[C@@H](O)CNC(=O)N1CC(Oc2cccc(C(F)(F)F)c2)C1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
ACACB O00763 3/20 0.47
ABHD6 Q9BV23 2/20 0.47
MGLL Q99685 1/20 0.47
EPHX2 P34913 1/20 0.46
NPSR1 Q6W5P4 1/20 0.44
FFAR1 O14842 2/20 0.43
ELANE P08246 2/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
SCN9A Q15858 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PDE9A O76083 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9596660 0.93 ACACB (0.48) KDM4EALDH1A1GAAACACBABHD6
SCHEMBL6587359 0.87 KCNH2 (0.46) ACACBEPHX2
SCHEMBL6588089 0.87 KCNH2 (0.46) ACACBEPHX2
SCHEMBL9596167 0.87 NPSR1 (0.52) KDM4EACACBABHD6MGLLEPHX2
SCHEMBL10918290 0.85 EPHX2 (0.50) KDM4EALDH1A1GAAACACBABHD6
SCHEMBL9597398 0.85 ALDH1A1 (0.50) KDM4EALDH1A1GAAACACBABHD6
SCHEMBL9597193 0.84 ACACB (0.53) ACACBABHD6MGLLEPHX2NPSR1
SCHEMBL9678580 0.84 EPHX2 (0.47) KDM4EACACBABHD6MGLLEPHX2
SCHEMBL6586914 0.84 EPHX2 (0.44) ALDH1A1ACACBEPHX2SLC6A2SLC6A4
SCHEMBL6586909 0.84 EPHX2 (0.44) ALDH1A1ACACBEPHX2SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1049671-B1 AZETIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS VERNALIS RES LTD (GB) 2004-04-21 EP claimed
US-6514961-B1 Such as anxiety and all forms of epilepsy, particularly in humans VERNALIS RESEARCH LIMITED (GB) 2003-02-04 US claimed
EP-1049671-A1 AZETIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS VERNALIS RESEARCH LIMITED (GB) 2000-11-08 EP claimed
WO-1999037614-A1 AZETIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS VERNALIS RESEARCH LIMITED (GB) 1999-07-29 WO claimed
EP-1049671-B1 AZETIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS VERNALIS RES LTD (GB) 2004-04-21 EP disclosed
US-6514961-B1 Such as anxiety and all forms of epilepsy, particularly in humans VERNALIS RESEARCH LIMITED (GB) 2003-02-04 US disclosed
EP-1049671-A1 AZETIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS VERNALIS RESEARCH LIMITED (GB) 2000-11-08 EP disclosed
WO-1999037614-A1 AZETIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS VERNALIS RESEARCH LIMITED (GB) 1999-07-29 WO disclosed